Volume Alert - RPRX 10.12 Repros Therapeutics Inc
Post# of 35
Posted On: 11/08/2014 12:24:12 AM
Volume Alert - RPRX 10.12 Repros Therapeutics Inc $RPRX Hit a high today of 10.25 Closing the day 11/07/14 at 10.12 +3.67 +56.90% With a day low of 7.66 and a total volume of 8,217,059.
RPRX Recent Posts: http://investorshangout.com/Repros-Therapeuti...PRX-55325/
RPRX Repros Therapeutics Inc Recent Headline News
Nasdaq stocks posting largest percentage increases
AP - Fri Nov 07, 5:08PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
SWIR: 33.90 (+0.30), PERI: 5.75 (-0.35), UNXL: 5.31 (+0.77), TREE: 47.03 (+3.12), SSRI: 5.20 (+0.88), STMP: 42.92 (+0.93), RPRX: 10.12 (+3.67), NYNY: 7.74 (-0.22), SHLD: 42.81 (+10.14), AREX: 10.73 (+1.88), PGNX: 5.37 (+0.76), ECYT: 6.03 (-0.46), SSO.TO: 5.90 (+0.95), SGMA: 7.21 (-0.64), SW.TO: 38.39 (-0.04), PLNR: 6.40 (+0.01)
Sears Soars Nearly +40% As REIT News Boosts Confidence
at The Street - Fri Nov 07, 2:42PM CST
Repros Therapeutics Inc (NASDAQ:RPRX), Sears Holdings Corp (NASDAQ:SHLD) and Allied Nevada Gold Corp. (NYSEMKT:ANV) are among the top-gaining billionaire stock picks of the day. On the losing end ar...
ANV: 1.05 (+0.19), AMSC: 1.17 (-0.19), RPRX: 10.12 (+3.67), SHLD: 42.81 (+10.14), STAY: 18.30 (-5.00)
Repros Therapeutics (RPRX) Stock Skyrockets After Meeting with FDA About Androxal
at The Street - Fri Nov 07, 10:07AM CST
Shares of Repros Therapeutics (RPRX) soared in morning trading Friday after the biopharmaceutical company held what it called a "constructive meeting" with the FDA regarding its testosterone-boosting drug Androxal.
RPRX: 10.12 (+3.67)
Repros Holds Constructive Meeting With FDA Regarding Androxal(R) NDA Filing
GlobeNewswire - Thu Nov 06, 3:21PM CST
-- No New Clinical Studies Requested
RPRX: 10.12 (+3.67)
Will Repros (RPRX) Miss Estimates This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 2:12PM CST
Repros Therapeutics Inc. (RPRX) has an earnings ESP of 0.00% and a Zacks Rank #4 (Sell).
MNK: 91.06 (-3.49), PBH: 32.79 (-4.53), RPRX: 10.12 (+3.67), HSP: 56.32 (-0.32)
63.7% Return Seen to Date on SmarTrend Repros Therapeutics Call (RPRX)
Comtex SmarTrend(R) - Mon Nov 03, 10:56AM CST
SmarTrend identified a Downtrend for Repros Therapeutics (NASDAQ:RPRX) on September 4th, 2014 at $17.86. In approximately 2 months, Repros Therapeutics has returned 63.72% as of today's recent price of $6.48.
RPRX: 10.12 (+3.67)
Technical Coverage of Pharma Stocks - Repros Therapeutics, Nektar Therapeutics, Akorn, AcelRx Pharma, and Pernix Therapeutics Holdings
PR Newswire - Mon Nov 03, 7:45AM CST
Investor-Edge has initiated coverage on the following equities: Repros Therapeutics Inc. (NASDAQ: RPRX), Nektar Therapeutics (NASDAQ: NKTR), Akorn Inc. (NASDAQ: AKRX), AcelRx Pharmaceuticals Inc. (NASDAQ: ACRX), and Pernix Therapeutics Holdings Inc. (NASDAQ: PTX). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Friday, October 31, 2014, the NASDAQ Composite ended at 4,630.74, up 1.41%, the Dow Jones Industrial Average advanced 1.13%, to finish the day at 17,390.52, and the S&P 500 closed at 2,018.05, up 1.17%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 778.85, up 0.51%, with the index also advancing 10.60% in the previous three months. Register for your complimentary reports on these five stocks at:
ACRX: 6.04 (+0.41), PTX: 9.09 (-0.17), AKRX: 36.59 (-1.29), RPRX: 10.12 (+3.67), NKTR: 13.35 (-0.21)
Repros to Webcast Investor and Analyst Day on October 31st
GlobeNewswire - Mon Oct 27, 3:01PM CDT
Repros Therapeutics Inc.(Nasdaq:RPRX) today announced that it will host a live webcast of its Investor and Analyst Day that is being held in New York City on Friday, October 31, 2014 beginning at 7:30 a.m. Eastern Time.
RPRX: 10.12 (+3.67)
Biotech Stock Roundup: AbbVie Calls off Shire Acquisition, Will Amgen Consider Breakup? - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Oct 22, 10:18AM CDT
Will Amgen (AMGN) go the Abbott (ABT) way and split into two separate companies?
PCYC: 133.49 (-3.63), NPSP: 27.49 (+0.15), RPRX: 10.12 (+3.67), AMGN: 160.25 (-0.10), ABBV: 61.50 (-1.21), REGN: 377.84 (+0.90), CELG: 106.45 (-0.69)
SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Possible Violations of Federal Securities Laws by the Board of Directors of Repros Therapeutics Inc. - RPRX
PR Newswire - Mon Oct 20, 12:33PM CDT
Levi & Korsinsky, LLP is investigating Repros Therapeutics Inc. ("Repros" or the "Company"
(NasdaqCM: RPRX) in connection with possible violations of federal securities laws.
RPRX: 10.12 (+3.67)
INVESTOR ALERT: Investigation of Repros Therapeutics Inc. Announced by Glancy Binkow & Goldberg LLP
Business Wire - Mon Oct 20, 9:36AM CDT
Glancy Binkow & Goldberg LLP announces that it is investigating potential claims on behalf of investors of Repros Therapeutics Inc. ("Repros Therapeutics" or the "Company" (NASDAQ: RPRX) concerning possible violations of federal securities laws. The investigation focuses on certain statements issued by the Company concerning the Company's business and financial prospects.
RPRX: 10.12 (+3.67)
Repros Therapeutics Down 64.6% Since SmarTrend Downtrend Call (RPRX)
Comtex SmarTrend(R) - Mon Oct 20, 9:08AM CDT
SmarTrend identified a Downtrend for Repros Therapeutics (NASDAQ:RPRX) on September 4th, 2014 at $17.86. In approximately 2 months, Repros Therapeutics has returned 64.61% as of today's recent price of $6.32.
RPRX: 10.12 (+3.67)
Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Repros Therapeutics Inc.
PR Newswire - Mon Oct 20, 8:00AM CDT
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Repros Therapeutics, Inc. ("Repros Therapeutics" or the "Company" (NasdaqCM: RPRX -News). Such investors are advised to contact Peretz Bronstein or his investor relations coordinator Eitan Kimelman at info@bgandg.com or 212-697-6484.
RPRX: 10.12 (+3.67)
INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Repros Therapeutics Inc. (RPRX) To Contact The Firm
PR Newswire - Fri Oct 17, 7:28PM CDT
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at Repros Therapeutics Inc. ("Repros" or the "Company" (NASDAQ: RPRX).
RPRX: 10.12 (+3.67)
GE and Urban Outfitters are big market movers
AP - Fri Oct 17, 3:31PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Friday on the New York Stock Exchange and the Nasdaq Stock Market:
URBN: 31.18 (+0.02), GE: 26.41 (+0.05), CLV: 10.77 (+0.44), RPRX: 10.12 (+3.67), CLF: 11.17 (+0.63), ATHN: 123.82 (-1.94), MS: 35.66 (+0.35)
EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Repros Therapeutics Inc. - RPRX
Business Wire - Fri Oct 17, 2:17PM CDT
The Rosen Law Firm announces that it is investigating potential securities claims against Repros Therapeutics Inc. (NASDAQ: RPRX) resulting from allegations that the Company may have issued materially misleading business information to the investing public.
RPRX: 10.12 (+3.67)
RPRX Recent Posts: http://investorshangout.com/Repros-Therapeuti...PRX-55325/
RPRX Repros Therapeutics Inc Recent Headline News
Nasdaq stocks posting largest percentage increases
AP - Fri Nov 07, 5:08PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
SWIR: 33.90 (+0.30), PERI: 5.75 (-0.35), UNXL: 5.31 (+0.77), TREE: 47.03 (+3.12), SSRI: 5.20 (+0.88), STMP: 42.92 (+0.93), RPRX: 10.12 (+3.67), NYNY: 7.74 (-0.22), SHLD: 42.81 (+10.14), AREX: 10.73 (+1.88), PGNX: 5.37 (+0.76), ECYT: 6.03 (-0.46), SSO.TO: 5.90 (+0.95), SGMA: 7.21 (-0.64), SW.TO: 38.39 (-0.04), PLNR: 6.40 (+0.01)
Sears Soars Nearly +40% As REIT News Boosts Confidence
at The Street - Fri Nov 07, 2:42PM CST
Repros Therapeutics Inc (NASDAQ:RPRX), Sears Holdings Corp (NASDAQ:SHLD) and Allied Nevada Gold Corp. (NYSEMKT:ANV) are among the top-gaining billionaire stock picks of the day. On the losing end ar...
ANV: 1.05 (+0.19), AMSC: 1.17 (-0.19), RPRX: 10.12 (+3.67), SHLD: 42.81 (+10.14), STAY: 18.30 (-5.00)
Repros Therapeutics (RPRX) Stock Skyrockets After Meeting with FDA About Androxal
at The Street - Fri Nov 07, 10:07AM CST
Shares of Repros Therapeutics (RPRX) soared in morning trading Friday after the biopharmaceutical company held what it called a "constructive meeting" with the FDA regarding its testosterone-boosting drug Androxal.
RPRX: 10.12 (+3.67)
Repros Holds Constructive Meeting With FDA Regarding Androxal(R) NDA Filing
GlobeNewswire - Thu Nov 06, 3:21PM CST
-- No New Clinical Studies Requested
RPRX: 10.12 (+3.67)
Will Repros (RPRX) Miss Estimates This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 2:12PM CST
Repros Therapeutics Inc. (RPRX) has an earnings ESP of 0.00% and a Zacks Rank #4 (Sell).
MNK: 91.06 (-3.49), PBH: 32.79 (-4.53), RPRX: 10.12 (+3.67), HSP: 56.32 (-0.32)
63.7% Return Seen to Date on SmarTrend Repros Therapeutics Call (RPRX)
Comtex SmarTrend(R) - Mon Nov 03, 10:56AM CST
SmarTrend identified a Downtrend for Repros Therapeutics (NASDAQ:RPRX) on September 4th, 2014 at $17.86. In approximately 2 months, Repros Therapeutics has returned 63.72% as of today's recent price of $6.48.
RPRX: 10.12 (+3.67)
Technical Coverage of Pharma Stocks - Repros Therapeutics, Nektar Therapeutics, Akorn, AcelRx Pharma, and Pernix Therapeutics Holdings
PR Newswire - Mon Nov 03, 7:45AM CST
Investor-Edge has initiated coverage on the following equities: Repros Therapeutics Inc. (NASDAQ: RPRX), Nektar Therapeutics (NASDAQ: NKTR), Akorn Inc. (NASDAQ: AKRX), AcelRx Pharmaceuticals Inc. (NASDAQ: ACRX), and Pernix Therapeutics Holdings Inc. (NASDAQ: PTX). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Friday, October 31, 2014, the NASDAQ Composite ended at 4,630.74, up 1.41%, the Dow Jones Industrial Average advanced 1.13%, to finish the day at 17,390.52, and the S&P 500 closed at 2,018.05, up 1.17%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 778.85, up 0.51%, with the index also advancing 10.60% in the previous three months. Register for your complimentary reports on these five stocks at:
ACRX: 6.04 (+0.41), PTX: 9.09 (-0.17), AKRX: 36.59 (-1.29), RPRX: 10.12 (+3.67), NKTR: 13.35 (-0.21)
Repros to Webcast Investor and Analyst Day on October 31st
GlobeNewswire - Mon Oct 27, 3:01PM CDT
Repros Therapeutics Inc.(Nasdaq:RPRX) today announced that it will host a live webcast of its Investor and Analyst Day that is being held in New York City on Friday, October 31, 2014 beginning at 7:30 a.m. Eastern Time.
RPRX: 10.12 (+3.67)
Biotech Stock Roundup: AbbVie Calls off Shire Acquisition, Will Amgen Consider Breakup? - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Oct 22, 10:18AM CDT
Will Amgen (AMGN) go the Abbott (ABT) way and split into two separate companies?
PCYC: 133.49 (-3.63), NPSP: 27.49 (+0.15), RPRX: 10.12 (+3.67), AMGN: 160.25 (-0.10), ABBV: 61.50 (-1.21), REGN: 377.84 (+0.90), CELG: 106.45 (-0.69)
SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Possible Violations of Federal Securities Laws by the Board of Directors of Repros Therapeutics Inc. - RPRX
PR Newswire - Mon Oct 20, 12:33PM CDT
Levi & Korsinsky, LLP is investigating Repros Therapeutics Inc. ("Repros" or the "Company"
(NasdaqCM: RPRX) in connection with possible violations of federal securities laws. RPRX: 10.12 (+3.67)
INVESTOR ALERT: Investigation of Repros Therapeutics Inc. Announced by Glancy Binkow & Goldberg LLP
Business Wire - Mon Oct 20, 9:36AM CDT
Glancy Binkow & Goldberg LLP announces that it is investigating potential claims on behalf of investors of Repros Therapeutics Inc. ("Repros Therapeutics" or the "Company"
(NASDAQ: RPRX) concerning possible violations of federal securities laws. The investigation focuses on certain statements issued by the Company concerning the Company's business and financial prospects. RPRX: 10.12 (+3.67)
Repros Therapeutics Down 64.6% Since SmarTrend Downtrend Call (RPRX)
Comtex SmarTrend(R) - Mon Oct 20, 9:08AM CDT
SmarTrend identified a Downtrend for Repros Therapeutics (NASDAQ:RPRX) on September 4th, 2014 at $17.86. In approximately 2 months, Repros Therapeutics has returned 64.61% as of today's recent price of $6.32.
RPRX: 10.12 (+3.67)
Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Repros Therapeutics Inc.
PR Newswire - Mon Oct 20, 8:00AM CDT
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Repros Therapeutics, Inc. ("Repros Therapeutics" or the "Company"
(NasdaqCM: RPRX -News). Such investors are advised to contact Peretz Bronstein or his investor relations coordinator Eitan Kimelman at info@bgandg.com or 212-697-6484. RPRX: 10.12 (+3.67)
INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Repros Therapeutics Inc. (RPRX) To Contact The Firm
PR Newswire - Fri Oct 17, 7:28PM CDT
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at Repros Therapeutics Inc. ("Repros" or the "Company"
(NASDAQ: RPRX). RPRX: 10.12 (+3.67)
GE and Urban Outfitters are big market movers
AP - Fri Oct 17, 3:31PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Friday on the New York Stock Exchange and the Nasdaq Stock Market:
URBN: 31.18 (+0.02), GE: 26.41 (+0.05), CLV: 10.77 (+0.44), RPRX: 10.12 (+3.67), CLF: 11.17 (+0.63), ATHN: 123.82 (-1.94), MS: 35.66 (+0.35)
EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Repros Therapeutics Inc. - RPRX
Business Wire - Fri Oct 17, 2:17PM CDT
The Rosen Law Firm announces that it is investigating potential securities claims against Repros Therapeutics Inc. (NASDAQ: RPRX) resulting from allegations that the Company may have issued materially misleading business information to the investing public.
RPRX: 10.12 (+3.67)
(0)
(0)Repros Therapeutics Inc. (RPRX) Stock Research Links
Scroll down for more posts ▼